| Literature DB >> 30453579 |
Seoung Rak Lee1, Dahae Lee2, Jae Sik Yu3, René Benndorf4, Sullim Lee5, Dong-Soo Lee6, Jungmoo Huh7, Z Wilhelm de Beer8, Yong Ho Kim9, Christine Beemelmanns10, Ki Sung Kang11, Ki Hyun Kim12.
Abstract
In recent years, investigations into the biochemistry of insect-associated bacteria have increased. When combined with analytical dereplication processes, these studies provide a powerful strategy to identify structurally and/or biologically novel compounds. Non-ribosomally synthesized cyclic peptides have a broad bioactivity spectrum with high medicinal potential. Here, we report the discovery of three new cyclic tripeptides: natalenamides A⁻C (compounds 1⁻3). These compounds were identified from the culture broth of the fungus-growing termite-associated Actinomadura sp. RB99 using a liquid chromatography (LC)/ultraviolet (UV)/mass spectrometry (MS)-based dereplication method. Chemical structures of the new compounds (1⁻3) were established by analysis of comprehensive spectroscopic methods, including one-dimensional (¹H and 13C) and two-dimensional (¹H-¹H-COSY, HSQC, HMBC) nuclear magnetic resonance spectroscopy (NMR), together with high-resolution electrospray ionization mass spectrometry (HR-ESIMS) data. The absolute configurations of the new compounds were elucidated using Marfey's analysis. Through several bioactivity tests for the tripeptides, we found that compound 3 exhibited significant inhibitory effects on 3-isobutyl-1-methylxanthine (IBMX)-induced melanin production. The effect of compound 3 was similar to that of kojic acid, a compound extensively used as a cosmetic material with a skin-whitening effect.Entities:
Keywords: Actinomadura sp.; fungus-growing termite; natalenamides A–C; skin-whitening effects; tripeptides
Mesh:
Substances:
Year: 2018 PMID: 30453579 PMCID: PMC6278286 DOI: 10.3390/molecules23113003
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1The chemical structures of natalenamides A–C (compounds 1–3).
1H (800 MHz) and 13C (200 MHz) NMR data of compounds 1–3 in d4-MeOH. a,b.
| 1 | 2 | 3 | ||||||
|---|---|---|---|---|---|---|---|---|
| Position |
| Position |
| Position |
| |||
| 1 | 60.4 d | 4.16 d (7.5) | 1 | 53.1 d | 4.42 m | 1 | 56.3 d | 4.53 dd (7.5, 5.0) |
| 2 | 32.1 d | 2.02 m | 2 | 42.4 t | 1.63 m | 2a | 38.5 t | 3.02 dd (14.0, 7.5) |
| 3 | 18.9 q | 0.91 d (7.0) | 3 | 26.2 d | 1.69 m | 2b | - | 3.24 dd (14.0, 5.0) |
| 4 | 19.9 q | 0.92 d (7.0) | 4 | 22.1 q | 0.92 d (6.5) | 3 | 138.9 s | - |
| 5 | 174.8 s | - | 5 | 23.7 q | 0.95 d (6.5) | 4/8 | 130.7 d | 7.21 m |
| 6 | 58.0 d | 4.20 dd (8.5, 4.5) | 6 | 174.9 s | - | 5/7 | 129.7 d | 7.23 m |
| 7a | 27.0 t | 1.95 m | 7 | 58.1 d | 4.09 dd (9.0, 4.5) | 6 | 127.8 d | 7.17 m |
| 7b | 2.48 m | 8a | 26.9 t | 1.82 m | 9 | 175.0 s | - | |
| 8a | 30.6 t | 2.27 m | 8b | - | 2.34 m | 10 | 57.9 d | 4.04 dd (9.0, 4.5) 8 |
| 8b | 2.36 m | 9a | 30.3 t | 2.16 m | 11a | 26.6 t | 1.74 m | |
| 9 | 181.8 s | - | 9b | - | 2.19 m | 11b | - | 2.29 m |
| 10 | 173.3 s | - | 10 | 181.6 s | - | 12 | 30.0 t | 2.15 m |
| 11 | 55.6 d | 4.63 dd (8.0, 5.0) | 11 | 173.4 s | - | 13 | 181.7 s | - |
| 12a | 38.8 t | 2.97 dd (14.0, 8.0) | 12 | 55.8 d | 4.72 dd (10.0, 5.0) | 14 | 174.0 s | - |
| 12b | - | 3.20 dd (14.0, 5.0) | 13a | 38.9 t | 2.89 dd (14.0, 10.0) | 15 | 55.8 d | 4.63 dd (10.0 4.5) |
| 13 | 138.8 s | - | 13b | - | 3.23 dd (14.0, 5.0) | 16a | 38.4 t | 2.80 dd (14.0, 10.0) |
| 14/18 | 130.6 d | 7.23 m | 14 | 138.6 s | - | 16b | - | 3.23 dd (14.0, 4.5) |
| 15/17 | 129.5 d | 7.24 m | 15/19 | 130.5 d | 7.21 m | 17 | 138.4 s | - |
| 16 | 127.8 d | 7.18 m | 16/18 | 129.4 d | 7.25 m | 18/22 | 130.2 d | 7.21 m |
| 19 | 173.2 s | - | 17 | 127.6 d | 7.19 m | 19/21 | 129.3 d | 7.23 m |
| - | - | - | 20 | 173.3 s | - | 20 | 127.4 d | 7.17 m |
| - | - | - | - | - | - | 23 | 173.8 s | - |
a Coupling constants (J, in parentheses) are in Hz, chemical shifts (δ) are in ppm; b 13C NMR data were assigned based on the HSQC and HMBC experiment.
Figure 2Key COSY () and HMBC (→) correlations for compounds 1–3.
Figure 3Cytotoxicity of compounds 1–3 against human cancer cell lines (MCF7 breast cancer cells, HeLa cervical cancer cells, A549 lung cancer cells, and HepG2 liver cancer cells). Cells were treated with compounds at the indicated concentrations. After 72 h of incubation, cell viability was analyzed according to the manufacturer’s instructions using the EZ-CyTox cell viability assay kit.
Figure 4Inhibitory effects of compounds 1–3 on lipopolysaccharide (LPS)-induced NO production in RAW264.7 cells. (A–C) Effects of compounds 1–3 on cell viability. (D–F) Inhibitory effects of compounds 1–3 on LPS-induced NO production in RAW264.7 cells.
Figure 5Inhibitory effects of compounds 1–3 on melanin content in B16F10 cells. (A–C) Effects of compounds 1–3 on cell viability. (D–F) Inhibitory effects of compounds 1–3 on IBMX-induced melanin production in B16F10 melanoma cells (mean ± SD, * p < 0.05 compared to the IBMX-treated value).